Alkermes (ALKS)

Create an Alert
28.91 -1.00  -3.34%   NASDAQ Jun 19, 8:00PM BATS Real time Currency in USD

Alkermes R&D Expense Quarterly:

35.80M for March 31, 2013
View Full Chart

Alkermes R&D Expense Quarterly Chart

    Alkermes Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 2   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 35.80M
    Dec. 31, 2012 31.32M
    Sept. 30, 2012 35.09M
    June 30, 2012 37.81M
    March 31, 2012 45.19M
    Dec. 31, 2011 40.49M
    Sept. 30, 2011 28.16M
    June 30, 2011 28.05M
    March 31, 2011 27.83M
    Dec. 31, 2010 22.50M
    Sept. 30, 2010 23.93M
    June 30, 2010 22.98M
    March 31, 2010 26.54M
    Dec. 31, 2009 22.58M
    Sept. 30, 2009 20.66M
    June 30, 2009 25.59M
    March 31, 2009 24.84M
    Dec. 31, 2008 22.67M
    Sept. 30, 2008 19.71M
    June 30, 2008 22.26M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
       
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro
    Dec. 31, 2001 Go Pro
    Sept. 30, 2001 Go Pro
    June 30, 2001 Go Pro
    March 31, 2001 Go Pro
    Dec. 31, 2000 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    ALKS R&D Expense Quarterly Benchmarks

    Companies
    Alexion Pharmaceuticals 74.54M
    Anika Therapeutics 1.583M
    AEterna Zentaris 4.401M

    ALKS R&D Expense Quarterly Rankings

    Overall 97th percentile
    393 of 16782
    Sector 93rd percentile
    92 of 1410 in Healthcare
    Industry 93rd percentile
    28 of 454 in Biotechnology

    ALKS R&D Expense Quarterly Range, Past 5 Years

    Minimum 19.71M Sep 2008
    Maximum 45.19M Mar 2012
    Average 28.20M

    Access watchlists and custom data alerts.
    Start your free account.

    Registering enables you to view unlimited pages per month.

    required
    required
    required
    required
    Get Started Now

    Already registered? Sign in here.

    document.write('');